<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913039</url>
  </required_header>
  <id_info>
    <org_study_id>2019-03-03</org_study_id>
    <nct_id>NCT03913039</nct_id>
  </id_info>
  <brief_title>Reduction of Prostate Biopsy Morbidity</brief_title>
  <official_title>Reduction of Prostate Biopsy Morbidity and Hospitalization Through a Modified Biopsy Protocol Bundle and Region-specific Antibiogram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate biopsy is typically performed via either the transrectal or transperineal approach.
      This study is a case-control study being done to determine if a novel prostate biopsy
      protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and
      broad antibiotic prophylaxis will reduce infectious complications and hospital readmission
      compared to current biopsy practices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective multi-center cohort case-control study comparing a novel
      transperineal prostate biopsy protocol integrating measures to reduce post procedural
      infection (Cases) to traditional transrectal prostate biopsies (Controls). Eligible subjects
      will be identified through administrative records in the Urology clinics affiliated with
      Maimonides Medical Center. Eligible patients will be counseled about the risks and benefits
      of participation and offered enrollment into the study. Demographic data including age,
      comorbidities and past medical history will be extracted from the medical record.

      Men meeting inclusion/exclusion criteria will be prospectively enrolled. The novel
      transperineal protocol will include the following: (Cases)

        1. Transperineal biopsy approach with avoidance of rectal flora

        2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where
           clinically indicated

        3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria

        4. Multi-antibiotic prophylaxis

        5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary,
           region-specific antibiotic resistance patterns.

      Traditional biopsy protocol includes: (Controls)

        1. Transrectal approach

        2. Standard 12-core template

        3. Surgeon-specific antibiotic prophylaxis

        4. Urine culture, prostate tissue culture and FQR rectal swab culture to define
           contemporary, region-specific antibiotic resistance patterns.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinically significant post-biopsy complications</measure>
    <time_frame>30 Days</time_frame>
    <description>1. Rate of any clinically significant post-biopsy complications including infectious complications and hospital readmissions within 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Number of individual complications within 30 days</measure>
    <time_frame>30 Days</time_frame>
    <description>1. Individual complications within 30 days including urinary retention, hematuria, urinary tract infection, hospitalization</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>transperineal protocol</arm_group_label>
    <description>Transperineal biopsy approach with avoidance of rectal flora
MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated
Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria
Multi-antibiotic prophylaxis
Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional biopsy</arm_group_label>
    <description>Transrectal approach
Standard 12-core template
Surgeon-specific antibiotic prophylaxis
Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transperineal biopsy Protocol</intervention_name>
    <description>Transperineal biopsy approach with avoidance of rectal flora
MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated
Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria
Multi-antibiotic prophylaxis
Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.</description>
    <arm_group_label>transperineal protocol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males with clinical indication for a prostate biopsy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients greater than 18 years of age

          -  Indication for prostate biopsy

        Exclusion Criteria:

          -  Female patients

          -  Male patients under 18 years of age

          -  No indication for prostate biopsy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Assessment of Prostate Cancer treatment - - only males qualify.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ariel Schulman, MD</last_name>
    <phone>7182836903</phone>
    <email>ASchulman@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Meeder</last_name>
    <phone>7182837253</phone>
    <email>smeeder@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Schulman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Ariel Schulman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03913039/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

